Bristol-Myers Squibb announces U.S. FDA approval of Opdivo (nivolumab)
Bristol-Myers Squibb announced that the FDA has approved Opdivo (nivolumab). OPDIVO is a human programmed death receptor-1 blocking antibody indicated for treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive. December 22, 2014